$1.76
2.92% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

ProQR Therapeutics N.V. Stock price

$1.76
+0.44 33.33% 1M
-1.91 52.04% 6M
-0.89 33.58% YTD
-0.16 8.33% 1Y
+1.09 161.09% 3Y
-3.87 68.74% 5Y
-18.29 91.22% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 2.92%
ISIN
NL0010872495
Symbol
PRQR
Sector
Industry

Key metrics

Market capitalization $185.17m
Enterprise Value $58.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.87
P/S ratio (TTM) P/S ratio 9.09
P/B ratio (TTM) P/B ratio 2.17
Revenue growth (TTM) Revenue growth 82.38%
Revenue (TTM) Revenue $20.36m
EBIT (operating result TTM) EBIT $-36.29m
Free Cash Flow (TTM) Free Cash Flow $-39.98m
Cash position $143.03m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 7.35
EV/Sales forward 2.32
Short interest 1.10%
Show more

Is ProQR Therapeutics N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

ProQR Therapeutics N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a ProQR Therapeutics N.V. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a ProQR Therapeutics N.V. forecast:

Buy
100%

Financial data from ProQR Therapeutics N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
20 20
82% 82%
100%
- Direct Costs 2.95 2.95
-
14%
17 17
-
86%
- Selling and Administrative Expenses 8.53 8.53
24% 24%
42%
- Research and Development Expense 42 42
37% 37%
207%
-33 -33
1% 1%
-164%
- Depreciation and Amortization 2.95 2.95
2% 2%
14%
EBIT (Operating Income) EBIT -36 -36
1% 1%
-178%
Net Profit -32 -32
11% 11%
-159%

In millions USD.

Don't miss a Thing! We will send you all news about ProQR Therapeutics N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ProQR Therapeutics N.V. Stock News

Neutral
GlobeNewsWire
9 days ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th An...
Neutral
GlobeNewsWire
13 days ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
19 days ago
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thurs...
More ProQR Therapeutics N.V. News

Company Profile

ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.

Head office Netherlands
CEO Daniel Boer
Employees 166
Founded 2012
Website www.proqr-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today